Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Chrono-log Corp.
| Company | Chrono-log Corp. |
|---|---|
| Instrument name | Optical Aggregation Systems Models 490 4+, 490 4+4 |
| Contact | Sal Pema |
| City State | Havertown, PA |
| Phone | 610-853-1130 or 800-247-6665 |
| Website | |
| First year sold | 2017 |
| List price/Model type | —/benchtop |
| Dimensions (H × W × D)/Weight/Instrument footprint | per each 4-channel module: 8.5 × 14 × 15 in./19.3 lbs./1.5 sq. ft. |
| No. of units in clinical use in U.S./Outside U.S. | — |
| Composition of installs: Hospital lab/Reference lab/Other | — |
| Targeted daily, monthly, annual test volume | — |
| Operational type | discrete |
| Country where analyzer designed/Manufactured | U.S./U.S. |
| Company manufactures instrument | yes (also sold via distribution partners) |
| FDA-approved clotting-based tests | — |
| FDA-approved chromogenic tests | — |
| FDA-approved immunologic tests | platelet agglutination with ristocetin |
| Other FDA-approved tests | LTA platelet aggregation, ristocetin cofactor assay |
| User-defined tests in clinical use | LTA platelet aggregation, ristocetin cofactor assay |
| Tests in development or awaiting FDA 510(k) clearance | — |
| Methodologies supported | turbidimetric for measuring platelet aggregation in PRP and ristocetin cofactor assay |
| Number of different measured assays onboard simultaneously | 4–8 |
| Number of different assays programmed and calib. at one time | 4–8 |
| No. of user-definable (open) channels/No. active simultaneously | 4–8/4–8 |
| Factor assays require manual manipulation or dilutions | yes (manual dilutions) |
| Test throughput per hour/Assay run time | 6 (24–48 tests in throughput)/5 min. minimum |
| Design of sample-handling system | manual |
| Operates on whole blood or spun plasma | spun plasma |
| Reagent type | self-contained multiuse vials; open reagent system (liquid, lyophilized [reconstituted manually]) |
| Reagent barcode-reading capability | no |
| No. of reagent containers held onboard/Reagents ready to use | —/requires operator prehandling |
| Reagent lot tracking/Reagent inventory/Reagents refrigerated onboard | no/no/no |
| Reagents, consumables loaded without interrupting testing | yes (consumables) |
| Instrument uses proprietary or third-party reagents | proprietary reagents |
| Maximum time same lot number of reagents can be used | 18 months–3 years |
| Walkaway capability/Walkaway duration | yes/5 min. or 4–8 specimens or 4–8 tests |
| Min.–max. specimen volume that can be aspirated at one time | 250–500 µL |
| Min. sample volume required for PT/PTT/Factor VIII activity | — |
| Types of disposables used | cuvettes, stir bars, pipette tips |
| Primary tube sampling supported/Pierces caps on primary tubes | no/no |
| Accommodates most standard tube sizes/Nonstandard sizes | no/no |
| Sample barcode-reading capability/Autodiscrimination | no/no |
| Auto tracks product volume/Measures number of tests remaining | no/no |
| Short sample detection | no |
| Clot detection as preanalytical variable in plasma sample | no |
| Auto detects adequate reagents for aspiration or analysis | no |
| Detection or quantitation for hemolysis, turbidity, icterus, lipemia | no |
| Dilutes patient samples onboard | no |
| Automatic rerun capability/Auto reflex testing capability | yes/no |
| Lag time during which hypercoagulable sample not detected | no |
| User can adjust reagent volumes/Sample volumes | yes/yes |
| User can adjust No. of reagents/Sources of reagents | yes/yes |
| User can adjust incubation times/Reading times | yes/yes |
| Autocalibration/Calibrants stored onboard | yes/no |
| Multipoint calibration supported/Recommended frequency | yes/annually |
| • PT alone | — |
| • PT, PTT | — |
| • Fibrinogen | — |
| • Factor VIII activity assay | — |
| • D-dimer | — |
| Time delay from ordering stat to aspiration of sample | — |
| How labs get LOINC codes for results | email query |
| Onboard real-time QC/Onboard software capability to review QC | yes/no |
| Information that can be barcode-scanned on instrument | barcode scanning not offered |
| Compatible with laboratory automation systems | no |
| Data-management capability/LIS or EHR systems interfaced | onboard/none |
| Interface supplied by instrument vendor | no |
| Results transferred to LIS as soon as test time complete | no |
| Bidirectional interface capability | no |
| Remote servicing provided/UPS backup power supply | no/no |
| Instrument connections to transfer information | — |
| Interface standards supported | — |
| Information transferred to data-management software | — |
| Avg. time for basic user training | — |
| Approximate scheduled maintenance time | preventive maintenance and calibration by clinical engineering recommended annually |
| Maintenance records kept onboard | yes |
| Warranty with purchase/Annual service contract cost (24/7) | yes/— (cost dependent on contract) |
| Distinguishing features (supplied by company) | continuously monitors and regulates temperature and stirring; optical calibration can be performed by laboratory personnel using no-cost water samples; customized color-coding options |